u/Accountable_Finance

GILD passed the author's strict fundamental screen, boasting a 32% FCF margin, 39% R&D intensity, and a 48% P/E discount to its 5-year average. High free cash flow and significant R&D investment combined with a massive historical discount position it to successfully navigate the patent cliff. Buy GILD as a fundamentally sound survivor of the upcoming patent cycle. General pipeline failures or inability to commercialize R&D investments effectively.

MRK trades at a 33% P/E discount to its 5-year average, with a 19% FCF margin and 80 active Phase 3 trials. The market is over-discounting the 2028 Keytruda patent expiration and ignoring Merck's robust pipeline, recent M&A, and restructuring efforts. Buy MRK as a compelling value opportunity insulated by a strong pipeline and a 2.93% dividend yield. The pipeline and recent acquisitions fail to adequately replace the massive revenue drop-off when Keytruda exclusivity ends.